

Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis (IPF)

Shigeki Saito^{1*}, Cheng Han H. Chung¹, Alex Jacob¹, Nebil Nuradin¹, Amy E. Meyer¹, Toshie Saito³, Haoran Yang^{1,2,4}, Jay K. Kolls^{1,2,4}, Victor J. Thannickal¹, Yao-Zhong Liu^{5#}, Joseph A. Lasky^{1#}

1 Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA

2 Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA

3 Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

4 Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, LA, USA

5 Department of Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA

ssaito@tulane.edu

cchung3@tulane.edu

ayacob@tulane.edu

nnuradin@tulane.edu

ameyer6@tulane.edu

toshies@stanford.edu

hyang11@tulane.edu

jkolls@tulane.edu

vthannickal@tulane.edu

yliu8@tulane.edu

jlasky@tulane.edu

* Corresponding author

Section of Pulmonary Diseases, Critical Care and Environmental Medicine

Department of Medicine

Tulane University School of Medicine, New Orleans, LA, USA

Phone: (504) 988-2251; Fax: (504) 988-2144

Address: 1430 Tulane Ave., Box 8509, New Orleans, LA 70112-2699, USA

contributed equally

ABSTRACT

Rationale and objectives

The role of human lung megakaryocytes in homeostasis and their dynamics in disease states remain unknown. We sought to investigate whether megakaryocyte/platelet gene signatures are altered in IPF.

Methods

We analyzed publicly available transcriptome datasets of lung tissue, bronchoalveolar lavage (BAL) cells, and peripheral whole blood from IPF patients and healthy controls. Enrichment of megakaryocyte and platelet gene signatures in those datasets were estimated using xCell, a novel computational method. Furthermore, we analyzed whether mean platelet volume (MPV) and platelet counts in peripheral blood are associated with lung transplant-free survival in our IPF cohort.

Results

In lung tissue, megakaryocyte scores were significantly lower in IPF than in controls. In BAL cells, platelet scores were significantly lower in IPF than in controls, and lower platelet scores were associated with lower lung transplant-free survival in IPF. In contrast, in blood, megakaryocyte scores were significantly higher in IPF than in controls, and higher megakaryocyte scores were associated with lower disease progression-free survival in IPF. Furthermore, higher MPV was associated with lower transplant-free survival in our IPF cohort, independent of age, sex, forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO).

Conclusions

In IPF, megakaryocyte/platelet gene signatures were altered in a compartment-specific manner. Moreover, those signatures and MPV in blood were associated with important clinical outcomes such as transplant-free survival. These findings provide new insights into altered megakaryocyte/platelet biogenesis in IPF and suggest the potential utility of megakaryocyte/platelet-based biomarkers in IPF.

Key Words: idiopathic pulmonary fibrosis (IPF); megakaryocyte; platelet; mean platelet volume (MPV), transcriptome; xCell

INTRODUCTION

A recent study in mice indicated that platelet-releasing megakaryocytes reside in the lung interstitium as well as within lung blood vessels, and that the lung is a site of platelet biogenesis (1). Other studies have also reported that megakaryocytes are present in mouse lungs and that they are immunomodulatory (e.g., antigen presentation to T cells) (2, 3).

The presence of megakaryocytes in human lungs has also been reported in SARS-CoV-2 infection (4–7); however, the characteristics and role of lung megakaryocytes in homeostatic conditions, as well as disease conditions such as idiopathic pulmonary fibrosis (IPF), are not well understood. We investigated whether megakaryocyte/platelet gene signatures are altered in IPF by analyzing publicly available transcriptome datasets with xCell, a novel computational method. We found that megakaryocyte/platelet gene signatures in lung, BAL cells, and blood are altered in IPF. We also found that a platelet gene signature in BAL cells, a megakaryocyte gene signature in blood, and mean platelet volume (MPV) in blood were all associated with important clinical outcomes such as lung transplant-free survival. Of note, higher MPV was associated with lower lung transplant-free survival in our IPF cohort, independent of age, sex, lung forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO). These findings provide new insights into altered megakaryocyte/platelet biogenesis in IPF and suggest the potential utility of megakaryocyte/platelet-based biomarkers in IPF.

METHODS

Generation of gene enrichment scores using xCell: Comparison of the scores between IPF and controls

We analyzed IPF transcriptome datasets in Table 1. To generate gene enrichment scores for megakaryocytes and platelets, we utilized xCell (8) (<https://xcell.ucsf.edu/>), a novel computational method that assesses enrichment of individual cell types based on gene expression profile. An xCell matrix comprising gene expression profiles of 64 cell types (including megakaryocytes and platelets) was used as the reference matrix. To determine whether megakaryocyte gene signature and/or platelet gene signature are altered in IPF patients compared to controls, the xCell gene enrichment scores for megakaryocytes and platelets were compared between IPF and controls using unpaired t-test or Mann-Whitney test. Correlation between enrichment scores was assessed using Pearson or Spearman correlation test. A p-value <0.05 was considered statistically significant. Statistical analyses were performed using GraphPad Prism software.

Survival analysis in the dataset GSE70867 (BAL cell transcriptome)

For a platelet gene signature in BAL cell transcriptome, we compared lung transplant-free survival between patients with higher platelet enrichment scores (above the median) and patients with

lower platelet enrichment scores (below the median) using a log-rank test. A p-value <0.05 was considered statistically significant.

Survival analysis in the dataset GSE93606 (blood transcriptome)

For gene signatures for megakaryocytes and platelets in peripheral whole blood transcriptome, we compared the disease progression-free survival (i.e., survival without significant [$>10\%$] decline in FVC over six months) between patients with high megakaryocyte/platelet enrichment scores (above the median) and patients with lower megakaryocyte/platelet enrichment scores (below the median), using a log-rank test. A p-value <0.05 was considered statistically significant.

Survival analysis in our IPF cohort

This study was approved by the Tulane University Institutional Review Board (Study Number: 2020-1146) with a waiver of informed consent, as this was a retrospective examination of clinically indicated data. IPF patients followed at Tulane Medical Center or University Medical Center New Orleans were enrolled in this study. Patient characteristics are shown in Table 2.

The diagnosis of IPF was made according to international guidelines (9). We compared the lung transplant-free survival between patients with higher mean platelet volume (MPV) (above the median) and patients with lower MPV (below the median) using a log-rank test. We also compared the survival between patients with higher platelet counts (above the median) and patients with lower platelet counts (below the median). A p-value <0.05 was considered statistically significant. For MPV, we further performed Cox hazards regression analysis (adjusted for age, sex, FVC, and DLCO) using IBM SPSS Statistics software.

RESULTS

IPF lung transcriptome is less enriched with megakaryocyte gene signature than controls

First, we compared xCell enrichment scores for megakaryocytes and platelets between IPF lungs and control lungs. In two independent datasets, GSE47460_GPL6480 and GSE47460_GPL14550, IPF lungs had significantly lower megakaryocyte scores than control lungs. In other words, the IPF lung transcriptome was significantly less enriched with a megakaryocyte gene signature than the control lung transcriptome (Figure 1A). Megakaryocyte scores were also significantly lower in other types of interstitial lung disease, such as non-specific interstitial pneumonia (NSIP) and hypersensitivity pneumonitis (HP), than control lungs (Figure 1B). However, there was no significant difference in platelet scores between IPF and control lungs (Figure 1C).

Gene signatures for megakaryocyte-erythroid progenitors (MEP) and other hematopoietic

progenitors are altered in IPF lungs

We next compared the scores for megakaryocyte-erythroid progenitors (MEP) between IPF lungs and control lungs. In mice, the lung has been shown to serve as a reservoir for megakaryocytes and other upstream progenitors (e.g., MEPs, hematopoietic stem cells [HSCs]) (1), although the presence of these progenitors in human lungs has not yet been shown.

The scores for MEP were higher in IPF lungs than in controls in the larger dataset, GSE47460_GPL14550, and a similar trend was observed in the smaller dataset, GSE47460_GPL6480 (Figure 2A).

We also compared the scores for erythrocytes (downstream of MEP) between IPF lungs and control lungs. In contrast to the scores for MEP, the scores for erythrocytes were lower in IPF lungs than controls in both datasets (Figure 2B), as seen in the scores for megakaryocytes (Figure 1A). These results suggest that there may be defects in differentiation/transition from MEP to megakaryocytes or erythroid progenitors/erythrocytes in IPF lungs.

We further compared the scores for hematopoietic progenitors upstream of MEP between IPF lungs and control lungs, keeping in mind that the presence of hematopoietic progenitors has been shown in mouse lungs but not yet in human lungs. Interestingly, the scores for HSC were lower, and the scores for common myeloid progenitors (CMP) were higher, in IPF lungs than in control lungs (Supplemental Figure 1, Figure 2C). This result raises a possibility that hematopoiesis may be deregulated in IPF lungs (if hematopoiesis truly exists in human lungs, as seen in mouse lungs).

Lower megakaryocyte scores are associated with more advanced stage, lower FVC, and lower microvascular endothelial scores in IPF

We sought to determine factors associated with low megakaryocyte scores in IPF lungs. We hypothesized that lower megakaryocyte scores might be associated with more advanced stage, poorer lung function, and more pulmonary vascular remodeling.

Disease stage

We analyzed the dataset GSE24206, which contains “early” IPF lungs (surgical biopsies) and “advanced” IPF lungs (explants). Megakaryocyte scores were significantly lower in advanced IPF than in early IPF (Figure 3A). We also analyzed datasets that sampled fibrotic areas and non-fibrotic areas from the same individuals in IPF (GSE99621 [three patients]) or combined pulmonary fibrosis with emphysema (CPFE) (GSE38934 [three patients]). In IPF, megakaryocyte scores appeared lower in scarred areas than in normal-appearing areas (Figure 3B). In CPFE, megakaryocyte scores appeared lower in fibrotic lesions than in emphysematous lesions (Figure 3C). These results are in line with the finding that megakaryocyte scores are lower in advanced IPF than in early IPF.

Lung function

In the dataset GSE47460_GPL14550, megakaryocyte scores were significantly correlated with

force vital capacity (FVC) in IPF, although the correlation was weak (Pearson $r = 0.2510$, $p=0.0059$) (Figure 4A). There was no significant correlation between megakaryocyte scores and diffusing capacity for carbon monoxide (DLCO) (Spearman $r = 0.1872$, $p=0.0502$) (Figure 4B).

Pulmonary vascular remodeling

In the dataset GSE47460_GPL14550, megakaryocyte scores were significantly correlated with microvascular endothelial cell scores in IPF lungs (Pearson $r = 0.5337$, $p<0.0001$) (Figure 5A, left). The correlation appeared slightly higher when patients with NSIP and HP were also included in the analysis ($r = 0.5664$, $p<0.0001$) (Figure 5A, right). In the dataset GSE24988, for patients with pulmonary fibrosis (who mostly had usual interstitial pneumonia [UIP]), there was a trend toward a lower megakaryocyte score in patients with mean pulmonary artery pressure (mPAP) >20 mmHg than in patients with mPAP ≤ 20 mmHg ($p=0.0577$) (Figure 5B). These results suggest that megakaryocyte scores may be inversely correlated with pulmonary vascular remodeling.

IPF BAL cell transcriptome is less enriched with platelet gene signature than that of healthy controls, and lower platelet scores are associated with worse lung transplant-free survival

In the dataset GSE70867, IPF BAL cells had significantly lower platelet scores than control BAL cells (Figure 6A). We also investigated whether platelet gene signatures in BAL cells predict survival of IPF patients in this dataset, where information on lung transplant-free survival is available. Patients with lower platelet scores (below the median) had significantly worse lung transplant-free survival rates than patients with higher scores (above the median) ($p<0.0001$) (Figure 6B). These results suggest that platelet biogenesis may be decreased in IPF lungs and that platelet gene signatures in BAL cells may be a novel biomarker to predict lung transplant-free survival in IPF.

IPF blood transcriptome is more enriched with a megakaryocyte gene signature than blood transcriptome of healthy controls

We investigated whether megakaryocyte/platelet gene signature in peripheral whole blood transcriptome is altered in IPF compared to healthy controls in two independent datasets (GSE33566 and GSE93606). We chose to investigate the transcriptome of peripheral whole blood rather than peripheral blood mononuclear cells (PBMCs) because we suspected that peripheral whole blood would be more enriched with megakaryocytes and platelets than PBMC. In both datasets, whole blood transcriptome of IPF patients had significantly higher megakaryocyte scores than whole blood transcriptome of age- and sex-matched healthy controls. In other words, the IPF blood transcriptome was significantly more enriched with megakaryocyte gene signature than control blood transcriptomes, in contrast to the lung transcriptome (Figure 7A). There was no significant difference in platelet enrichment scores between IPF and controls, although there was a trend toward higher platelet scores in IPF compared to controls (Figure 7B). There was weak

but significant negative correlation between megakaryocyte/platelet scores and FVC in the dataset GSE93606. Such correlation was not observed in the dataset GSE33566 (Supplemental Figure 2).

Higher megakaryocyte scores in blood transcriptome are associated with worse disease progression-free survival in IPF

In the dataset GSE93606, IPF patients with higher megakaryocyte scores had worse disease progression-free survival than IPF patients with lower megakaryocyte scores ($p=0.0096$) (Figure 8A). There was also a trend for worse disease progression-free survival in IPF patients with higher platelet scores compared to IPF patients with lower platelet scores ($p=0.1436$) (Figure 8B). This suggests that a megakaryocyte signature in peripheral whole blood may be a novel biomarker that can predict disease progression in IPF.

Higher mean platelet volume (MPV) in peripheral whole blood is associated with worse lung transplant-free survival in IPF, independent of age, sex, and lung function

We sought to determine whether mean platelet volume (MPV) and platelet counts in peripheral whole blood, two platelet parameters routinely measured in clinical practice (as a part of complete blood count [CBC]), are associated with lung transplant-free survival in IPF. We hypothesized that higher MPV may be associated with worse survival in IPF, given that an increase in blood megakaryocytes or immature platelets might be associated with higher MPV and that higher megakaryocyte scores in blood were associated with worse outcome. We also hypothesized that higher platelet counts may be associated with worse survival (higher mortality) in IPF, given that there was a trend toward worse disease progression-free survival in patients with higher platelet scores in the peripheral whole blood transcriptome.

In our IPF cohort (Table 2), there was a trend toward worse survival in patients with higher MPV (above the median [9.9 femtoliters]) compared to patients with lower MPV (below the median) ($p=0.0940$) (Figure 9A). On the other hand, higher platelet counts (above the median [227,000 per microliter]) were not significantly associated with lower lung transplant-free survival ($p=0.3408$) (Figure 9B). Of note, univariate analysis with Cox proportional hazards regression model (Table 3) revealed that higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival ($p=0.042$). More importantly, multivariate analysis (Table 3) revealed that higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, and DLCO ($p=0.031$) (Multivariate analysis 1, 2). Furthermore, higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, DLCO, and platelet counts ($p=0.012$) (Multivariate analysis 3). These results suggest that MPV in peripheral whole blood may be a simple yet novel biomarker to predict important clinical outcomes such as lung transplant-free survival in IPF. Our overall results are summarized in Table 4.

DISCUSSION

Although the presence of megakaryocytes has been reported in human lungs, the characteristics and role of lung megakaryocytes in IPF are not well understood. We tested our hypothesis that megakaryocyte/platelet gene signatures are altered in IPF lung, BAL cells, and blood by analyzing publicly available transcriptome datasets. We calculated gene signature enrichment scores using xCell, a novel bioinformatics tool that assesses enrichment of individual cell types based on gene expression profile. Our analyses indicated that megakaryocyte/platelet gene signatures were altered in IPF in a compartment-specific manner. We found that IPF lung transcriptome was less enriched with a megakaryocyte gene signature than controls. Lower megakaryocyte gene signature enrichment (lower megakaryocyte score) was associated with more advanced disease, poorer lung function, and greater pulmonary vascular remodeling. We also found that the IPF BAL cell transcriptome was less enriched with platelet gene signature compared to controls, and that lower enrichment (lower platelet score) in BAL cells was associated with lower lung transplant-free survival in IPF. In contrast, IPF blood transcriptome was more enriched with megakaryocyte gene signature than controls, and higher enrichment (higher megakaryocyte score) in blood was associated with decreased disease progression-free survival in IPF. Furthermore, we found that higher MPV in peripheral blood was associated with worse lung transplant-free survival in our IPF cohort.

The finding that the IPF lung transcriptome is less enriched with megakaryocyte gene signature than controls is intriguing. This seems to contradict a previous report that CD41+ megakaryocyte counts are increased in lung tissue of bleomycin-challenged mice (10), possibly reflecting the fact that the bleomycin-induced pulmonary fibrosis mouse model is not able to fully recapitulate human IPF. Our finding suggests a possibility that that IPF lungs harbor fewer (healthy) megakaryocytes due to their altered megakaryocyte niche (i.e., IPF lungs provide a less optimal niche for megakaryocytes) and that megakaryocytes (especially extravascular/interstitial megakaryocytes) are actually decreased in IPF lungs. So far, published single-cell RNA-seq analyses have failed to identify a cluster of lung megakaryocytes in fibrotic lung tissue (11–15). This may be because lung megakaryocytes are too rare or fragile to be isolated without any enrichment or a special protocol optimized for megakaryocytes. We expect that methods such as single-cell/nuclei RNA-seq with megakaryocyte enrichment techniques and spatial transcriptomics/proteomics will help us define a megakaryocyte niche in healthy and diseased lungs.

The finding that the IPF BAL cell transcriptome is less enriched with platelet gene signature than controls is also intriguing. This seems to contradict a previous report that higher platelet counts in

BAL fluid were correlated with worse pulmonary fibrosis in a bleomycin-induced pulmonary fibrosis mouse model (16), further supporting the distinct differences between this mouse model and human IPF. One could speculate that, in IPF, reduced lung megakaryocytes lead to decreased platelet production in lungs, resulting in less spillover of platelets into alveoli. The finding that lower enrichment (lower platelet score) in BAL cells was associated with worse survival in IPF suggests a possibility that platelet gene signature (and/or platelet counts) in BAL fluid may serve as a novel biomarker in IPF. Further studies are needed to explore this possibility.

We are also intrigued by the stark contrast in the megakaryocyte gene signature between lung transcriptome and blood transcriptome in IPF (i.e., IPF lungs showed less megakaryocyte gene signature enrichment than control lungs, whereas IPF blood showed more megakaryocyte gene signature enrichment than control blood). One possibility is that decreased megakaryocyte/platelet biogenesis in IPF lungs induces megakaryocyte/platelet biogenesis in bone marrow. For example, bone marrow may be producing more megakaryocytes and/or releasing more megakaryocytes into the circulation in response to factors released by fibrotic lungs (e.g., CXCL12 (10)) (Figure 10). The second possibility is that megakaryocytes cannot stay in the altered niche within IPF lungs and therefore escape into the circulation. The third possibility is that fibrotic lungs are “educating” circulating platelets and modifying their transcriptome, as shown in previous works on “tumor-educated platelets” (17). These possibilities could be addressed by further investigations of megakaryocytes/platelets in the circulation and/or bone marrow in IPF patients. For example, transcriptome analysis of those cells is expected to determine whether megakaryocytes and/or immature platelets are increased in IPF and whether platelets in IPF have a distinct gene expression profile.

The findings that the blood transcriptome is more enriched with a megakaryocyte gene signature, and that higher MPV in peripheral blood is associated with worse survival, are novel. A previous study reported that patients with IPF exhibit higher MPV values and lower platelet counts compared to healthy controls (18). Other studies reported increased platelet reactivity/activation in IPF (19, 20). However, none of these studies have investigated the association between platelet parameters and important clinical outcomes such as survival. A recent study reported that changes in neutrophil:lymphocyte ratio (NLR) and lymphocyte:platelet ratio (LPR) over 12 months are associated with clinical outcome in IPF (20). However, the authors did not report an association between MPV and clinical outcome. Our finding that higher MPV is associated with worse clinical outcomes needs to be validated in another IPF cohort. A recent study with a small IPF cohort reported (in a preprint) that higher platelet counts are associated with worse survival (21), but we did not find such an association in our IPF cohort. Their finding should be validated in larger cohorts. Four recent studies with large IPF cohorts reported that higher monocyte counts are associated with worse survival (22–25), but we failed to replicate their finding, probably

because our IPF cohort is much smaller than their cohorts. It remains to be seen whether MPV (or platelet counts) serve as a useful IPF prognostic factor alone and/or in combination with other complete blood count (CBC) parameters such as NLR and monocyte counts.

There are several limitations to our study.

One of the major limitations is that *in silico* prediction/estimation of gene signature enrichment for various types of cells in tissues is still far from perfect and is especially difficult in rare types of cells. It remains to be seen whether other *in silico* methods or algorithms outperform xCell, which integrates the advantages of gene enrichment with deconvolution approaches. xCell has been shown to outperform CIBERSORT, a major deconvolution-based method (26), but has not been compared with immunoStates, another deconvolution-based method which has been shown to outperform CIBERSORT (27). At any rate, no *in silico* algorithm is expected to be perfect in predicting cell composition/enrichment in tissue. Discoveries made using digital dissection methods must be rigorously validated using other technologies (e.g., enrichment for megakaryocytes followed by single-cell/nuclei RNA-seq; spatial transcriptomics/proteomics).

Another limitation is that a megakaryocyte gene signature derived from bone marrow megakaryocytes is unlikely to be fully applicable to lung megakaryocytes, because lung megakaryocytes are transcriptionally (and phenotypically) distinct from bone marrow megakaryocytes. For example, lung megakaryocytes have higher expression of MHC class II and other molecules related to antigen presentation compared to bone marrow megakaryocytes (1–3).

It remains unclear whether megakaryocytes and/or platelets contribute to the pathogenesis of IPF. Whether the observed decrease in megakaryocyte gene signature in IPF lung and increase in a megakaryocyte signature in IPF blood is the consequence or the cause of pulmonary fibrosis is currently unknown. A previous study with a bleomycin-induced pulmonary fibrosis mouse model suggested that megakaryocytes migrate to injured lung tissue partially through the CXCL12/CXCR4 axis and contribute to fibrogenesis by promoting the proliferation and trans-differentiation of fibroblasts through direct contact and TGF- β 1 signaling (10). However, a more recent study reported that megakaryocyte/platelet-specific TGF- β 1 conditional knockout mice (PF4-Cre, TGF- β 1 floxed mice) were not protected against bleomycin-induced pulmonary fibrosis (21). We cannot exclude the possibility that megakaryocyte/platelet-derived molecules other than TGF- β 1 (e.g., PDGF, IGF-1, polyphosphate (28)) contribute to pulmonary fibrosis. Further mechanistic studies are needed to determine whether megakaryocytes and/or platelets contribute to the pathogenesis of pulmonary fibrosis.

It also remains unclear whether the human lung is a reservoir of megakaryocyte progenitors and a source of platelet biogenesis, as observed in mouse lungs. Our study suggests that gene

signatures of megakaryocyte progenitors are present in the human lung transcriptome, but this does not necessarily mean that those cells are actually present in human lungs. Further studies are needed to address this question.

In conclusion, in IPF, megakaryocyte/platelet gene signatures in lung, BAL cells, and blood are altered and may have prognostic value. Moreover, MPV, a platelet parameter routinely measured in clinical practice, may also have prognostic value. Further studies are needed to elucidate megakaryocyte/platelet biogenesis and to validate prognostic utility of megakaryocyte/platelet gene signatures as well as MPV in IPF.

Figure Legends

Figure 1. IPF lung transcriptome is less enriched with megakaryocyte gene signature than controls

In two independent datasets (GSE47460_GPL6480 and GSE47460_GPL14550), xCell enrichment scores for megakaryocytes and platelets were compared between lungs of IPF patients and lungs of control patients (who underwent surgery for the investigation of a nodule but had no chronic lung disease by CT or pathology).

(A) IPF lungs had significantly lower megakaryocyte enrichment scores than control lungs in both datasets.

(B) Megakaryocyte enrichment scores were also significantly lower in other types of interstitial lung diseases such as non-specific interstitial pneumonia (NSIP) and hypersensitivity pneumonitis (HP) than control lungs.

(C) There was no significant difference in platelet enrichment scores between IPF lungs and control lungs.

Figure 2. Gene signatures for megakaryocyte-erythroid progenitors (MEP) and other hematopoietic progenitors appear altered in IPF lungs

(A) Comparison of the xCell enrichment scores for megakaryocyte-erythroid progenitors (MEP, upstream of megakaryocytes) between IPF lungs and control lungs.

The scores for MEP were higher in IPF lungs than in the controls in the larger dataset (GSE47460_GPL14550). There was a similar trend in the smaller dataset (GSE47460_GPL6480).

(B) Comparison of the xCell enrichment scores for erythrocytes (downstream of MEP) between IPF lungs and control lungs. The erythrocyte scores were lower in IPF lungs than the controls in both datasets.

(C) Comparison of the xCell enrichment scores for hematopoietic progenitors upstream of MEP between IPF lungs and control lungs.

For the thin arrows in small boxes:

↑: the score is significantly higher in IPF than control

→: the score is not significantly different between IPF and control

↓: the score is significantly lower in IPF than control

Arrows to the left of the slash (/) are from GSE47460_GPL6480

Arrows to the right of the slash (/) are from GSE47460_GPL14550

Figure 3. Lower megakaryocyte scores are associated with more advanced stage, lower FVC, and lower microvascular endothelial scores in pulmonary fibrosis

(A) Megakaryocyte scores were significantly lower in “advanced” IPF (explants) than in “early” IPF

(surgical biopsies) in the dataset GSE24206.

(B) In IPF, megakaryocyte scores appeared lower in scarred areas than in normal-appearing areas in the dataset GSE99621, which sampled both fibrotic and non-fibrotic areas from the three IPF patients.

(C) In CPFE, megakaryocyte scores appeared lower in fibrotic lesions than in emphysematous lesions in the dataset GSE38934, which sampled both fibrotic and non-fibrotic areas from three patients.

Figure 4. Lower megakaryocyte scores are associated with lower FVC in IPF

(A, B) Correlation between megakaryocyte scores and FVC or DLCO in the dataset GSE47460_GPL14550.

(A) Megakaryocyte scores were weakly but significantly correlated with force vital capacity (FVC) in IPF (Pearson $r = 0.2510$, $p=0.0059$).

(B) There was no significant correlation between megakaryocyte scores and diffusing capacity (DLCO) (Spearman $r = 0.1872$, $p=0.0502$) (Figure 3B).

Figure 5. Lower megakaryocyte scores are associated with lower microvascular endothelial scores

(A) Correlation between megakaryocyte scores and microvascular endothelial scores in the dataset GSE47460_GPL14550.

Left: Megakaryocyte scores are significantly correlated with microvascular endothelial cell scores in IPF lungs (Pearson $r = 0.5337$, $p<0.0001$)

Right: The correlation appears slightly higher when patients with NSIP and HP are also included in the analysis ($r = 0.5664$, $p<0.0001$).

(B) There is a trend toward a lower megakaryocyte score in patients with mean pulmonary artery pressure (mPAP) >20 mmHg than in patients with $mPAP \leq 20$ mmHg ($p=0.0577$) in dataset GSE24988, which included patients with pulmonary fibrosis (who mostly had UIP).

Figure 6. IPF BAL cell transcriptome is less enriched with platelet gene signature than that of healthy controls, and lower platelet scores are associated with worse lung transplant-free survival

(A) In the dataset GSE70867 (Freiburg cohort in which the controls were available), xCell enrichment platelet scores for BAL cells were compared between IPF patients and controls.

IPF BAL cells had significantly lower platelet enrichment scores than control BAL cells.

(B) In the dataset GSE70867 (overall cohort = Freiburg + Siena + Leuven), lung transplant-free survival was compared between IPF patients with high platelet scores (i.e., higher than median) and low platelet scores (i.e., lower than median). Patients with lower platelet scores had significantly worse lung transplant-free survival than patients with higher platelet scores (log-rank

test $p < 0.0001$, hazard ratio=2.190 [95% CI: 1.476–3.249]).

Figure 7. IPF whole blood transcriptome is more enriched with megakaryocyte gene signature than whole blood transcriptome of healthy controls

(A, B) xCell enrichment scores for megakaryocytes and platelets in whole blood transcriptome were compared between IPF and control in two independent datasets (GSE33566 and GSE93606).

(A) Whole blood transcriptome of IPF patients had significantly higher megakaryocyte scores than whole blood transcriptome of healthy controls.

(B) There was no significant difference in platelet enrichment scores between IPF and controls.

Figure 8. Higher megakaryocyte scores in blood transcriptome are associated with worse disease progression-free survival in IPF

(A, B, C, D) In the dataset GSE93606, disease progression-free survival was compared between IPF patients with high scores (i.e., above the median) and low scores (i.e., below the median) for megakaryocyte (A) and platelets (B). Disease progression was defined as death or decline in FVC >10% over a six-month period in this dataset.

(A) IPF patients with higher megakaryocyte scores in blood transcriptome had worse disease progression-free survival than IPF patients with lower megakaryocyte scores (log-rank test $p = 0.0096$, hazard ratio=2.535 [95% CI: 1.254–5.128]).

(B) There was no statistically significant difference in disease progression-free survival between IPF patients with higher platelet scores (above the median) and lower platelet scores (below the median) (log-rank test $p = 0.1436$, hazard ratio=1.679 [95% CI: 0.8384–3.362]).

Figure 9. Higher mean platelet volume (MPV) in peripheral whole blood is associated with worse lung transplant-free survival in IPF

(A) In our IPF patients for whom data on mean platelet volume (MPV) were available ($n = 165$), there was a trend toward worse lung transplant-free survival in patients with higher MPV (above the median [9.9 femtoliters]) compared to patients with lower MPV (below the median) (log-rank test $p = 0.0940$, hazard ratio=1.473 [95% CI: 0.9362–2.317]).

(B) In our IPF patients for whom data on platelet counts were available ($n = 184$), higher platelet counts (above the median [227,000 per microliter]) were not significantly associated with decreased lung transplant-free survival (log-rank test $p = 0.3408$, hazard ratio=1.231 [95% CI: 0.8029–1.887]).

Figure 10. Working hypothesis (proposed schema): Altered megakaryocyte/platelet biogenesis in IPF

Supplemental Figure Legends

Supplemental Figure 1. Comparison of the xCell enrichment scores for hematopoietic progenitors upstream of MEP between IPF lungs and control lungs.

Right panels: GSE47460_GPL6480 / Left panels: GSE47460_GPL14550

In both datasets, the scores for hematopoietic stem cells (HSC) were lower in IPF lungs than in control lungs, whereas the scores for common lymphoid progenitors (CLP) and common myeloid progenitors (CMP) were higher in IPF lungs than in control lungs.

Supplemental Figure 2. Correlation between blood megakaryocyte/platelet scores and lung function (FVC, DLCO)

(A) No significant correlation was observed between the scores and lung function in the dataset GSE33566.

(Megakaryocytes and FVC: Spearman $r = -0.09331$, $p = 0.5237$; megakaryocytes and DLCO: Spearman $r = 0.07781$, $p = 0.6721$; platelets and FVC: Spearman $r = -0.1098$, $p = 0.4524$; platelets and DLCO: Spearman $r = 0.03379$, $p = 0.8373$)

(B) There is weak but significant negative correlation between scores and FVC in the dataset GSE93606.

(Megakaryocytes and FVC: Spearman $r = -0.4757$, $p = 0.0002$; megakaryocytes and DLCO: Spearman $r = -0.2193$, $p = 0.1044$; platelets and FVC: Spearman $r = -0.3329$, $p = 0.0114$; platelets and DLCO: Spearman $r = -0.1173$, $p = 0.3892$)

Table 1. Transcriptome datasets analyzed in this study

Tissue type	NCBI Gene Expression Omnibus (GEO) accession number
Lung tissue	GSE47460_GPL6480
	GSE47460_GPL14550
	GSE24206
	GSE99621
	GSE38934
	GSE24988
BAL cells	GSE70867
Peripheral whole blood	GSE33566
	GSE93606

Table 2. Clinical characteristics of our IPF patient cohort (n= 184)

Age (years): mean (SD), median (IQR)	70.2 (8.53), 69.6 (64.5–75.7)
Sex: Male, n (%)	129 (70.1)
FVC (% predicted): mean (SD), median (IQR)	69.9 (18.8), 69.0 (55.7–81.0)
DLCO (% predicted): mean (SD), median (IQR)	46.9 (14.3), 45 (37.5–55.5)
MPV (femtoliters): mean (SD), median (IQR)	9.74 (1.32), 9.90 (8.90–10.6)
Platelet Counts (per microliter): mean (SD), median (IQR)	234 (66.1), 229 (190–264)
Monocyte Counts ($\times 10^9$ per liter): mean (SD), median (IQR)	0.697 (0.2350), 0.670 (0.55–0.84)

Data on age, sex, and platelet counts were available from all 184 patients.

Data on FVC, DLCO, MPV, and monocyte counts were available from 177, 169, 165, and 167 patients, respectively.

* SD = standard deviation; IQR = interquartile range; FVC = forced vital capacity; DLCO = diffusing capacity of the lung for carbon monoxide; MPV = mean platelet volume

Table 3. Cox proportional hazards regression model

	P value	Hazard Ratio	95% Confidence Interval
Univariate Analysis			
Age	0.006	1.037	1.010–1.064
Sex (male compared to female)	0.162	1.446	0.863–2.425
FVC (% predicted)	<0.001	0.970	0.957–0.984
DLCO (% predicted)	<0.001	0.961	0.944–0.979
MPV	0.042	1.210	1.007–1.453
Platelet Counts	0.114	1.003	0.999–1.006
Monocyte Counts	0.502	1.435	0.500–4.116
Multivariate Analysis 1			
Age	0.467	1.011	0.982–1.040
Sex (male compared to female)	0.236	1.467	0.779–2.763
FVC (% predicted)	0.031	0.982	0.966–0.998
DLCO (% predicted)	0.002	0.969	0.950–0.989
MPV	0.031	1.235	1.020–1.496
Multivariate Analysis 2			
Age	0.172	1.020	0.992–1.048
Sex (male compared to female)	0.477	1.245	0.680–2.282
FVC (% predicted)	0.007	0.980	0.965–0.994
DLCO (% predicted)	0.009	0.976	0.959–0.994
Platelet Counts	0.147	1.003	0.999–1.007
Multivariate Analysis 3			
Age	0.454	1.011	0.982–1.040
Sex (male compared to female)	0.122	1.670	0.872–3.200
FVC (% predicted)	0.026	0.982	0.967–0.998
DLCO (% predicted)	0.003	0.971	0.952–0.990
MPV	0.012	1.291	1.056–1.577
Platelet Counts	0.075	1.004	1.000–1.009

We performed univariate analysis with variables that have been shown to be associated with survival in multiple studies. Then we performed multivariate analysis with variables with $p < 0.20$ in univariate analysis.

Univariate analysis revealed that higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival ($p = 0.042$, hazard ratio = 1.210 [95% CI: 1.007–1.453]).

Multivariate analysis revealed that higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, and DLCO

($p=0.031$, hazard ratio=1.235 [95% CI: 1.020–1.496]) (Multivariate analysis 1, 2). Moreover, higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, DLCO, and platelet counts ($p=0.012$, hazard ratio=1.291 [95% CI: 1.056–1.577]) (Multivariate analysis 3).

Table 4. Overall summary of our findings

xCell Enrichment Score derived from transcriptome	<u>Megakaryocyte</u> Score	<u>Platelet</u> Score
Lung tissue	Control > IPF	Control ≈ IPF
BAL cells	(Not applicable; Megakaryocytes have not been shown to be present in BAL fluid)	Control > IPF In IPF: <u>lower</u> score = lower lung transplant-free survival
Peripheral whole blood	Control < IPF In IPF: <u>higher</u> score = lower disease progression-free survival	Control ≈ IPF
Platelet parameters routinely reported in complete blood count (CBC)	Megakaryocyte	Platelet
MPV (mean platelet volume)	(Not applicable)	In IPF: <u>higher</u> MPV = lower lung transplant-free survival
Platelet counts	(Not applicable)	In IPF: no clear association between platelet counts and outcome

References

1. Lefrançois E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD, Passegué E, Looney MR. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature* 2017;544:105–109.
2. Pariser DN, Hilt ZT, Ture SK, Blick-Nitko SK, Looney MR, Cleary SJ, Roman-Pagan E, Saunders J, Georas SN, Veazey J, Madere F, Santos LT, Arne A, Huynh NP, Livada AC, Guerrero-Martin SM, Lyons C, Metcalf-Pate KA, McGrath KE, Palis J, Morrell CN. Lung megakaryocytes are immune modulatory cells. *J Clin Invest* 2021;131:137377.
3. Yeung AK, Villacorta-Martin C, Hon S, Rock JR, Murphy GJ. Lung megakaryocytes display distinct transcriptional and phenotypic properties. *Blood Adv* 2020;4:6204–6217.
4. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med* 2020;8:681–686.
5. Rapkiewicz AV, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, Thomas S, Adler NM, Charytan DM, Gasmi B, Hochman JS, Reynolds HR. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. *EClinicalMedicine* 2020;24:100434.
6. Duarte-Neto AN, Monteiro RAA, da Silva LFF, Malheiros DMAC, de Oliveira EP,

- Theodoro-Filho J, Pinho JRR, Gomes-Gouvêa MS, Salles APM, de Oliveira IRS, Mauad T, Saldiva PHN, Dolhnikoff M. Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy. *Histopathology* 2020;77:186–197.
7. Valdivia-Mazeyra MF, Salas C, Nieves-Alonso JM, Martín-Fragueiro L, Bárcena C, Muñoz-Hernández P, Villar-Zarra K, Martín-López J, Ramasco-Rueda F, Fraga J, Jiménez-Heffernan JA. Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature. *Virchows Arch* 2021;478:487–496.
8. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. *Genome Biol* 2017;18:220.
9. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, *et al.* Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018;198:e44–e68.
10. Zhou Y, Zhang B, Li C, Huang X, Cheng H, Bao X, Zhao F, Cheng Q, Yue S, Han J, Luo Z. Megakaryocytes participate in the occurrence of bleomycin-induced pulmonary fibrosis. *Cell*

Death Dis 2019;10:648.

11. Reyfman PA, Walter JM, Joshi N, Anekalla KR, McQuattie-Pimentel AC, Chiu S, Fernandez R, Akbarpour M, Chen C-I, Ren Z, Verma R, Abdala-Valencia H, Nam K, Chi M, Han S, Gonzalez-Gonzalez FJ, Soberanes S, Watanabe S, Williams KJN, Flozak AS, Nicholson TT, Morgan VK, Winter DR, Hinchcliff M, Hrusch CL, Guzy RD, Bonham CA, Sperling AI, Bag R, *et al.* Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2019;199:1517–1536.
12. Adams TS, Schupp JC, Poli S, Ayaub EA, Neumark N, Ahangari F, Chu SG, Raby BA, Deluliis G, Januszyk M, Duan Q, Arnett HA, Siddiqui A, Washko GR, Homer R, Yan X, Rosas IO, Kaminski N. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. *Sci Adv* 2020;6:eaba1983.
13. Habermann AC, Gutierrez AJ, Bui LT, Yahn SL, Winters NI, Calvi CL, Peter L, Chung M-I, Taylor CJ, Jetter C, Raju L, Roberson J, Ding G, Wood L, Sucre JMS, Richmond BW, Serezani AP, McDonnell WJ, Mallal SB, Bacchetta MJ, Loyd JE, Shaver CM, Ware LB, Bremner R, Walia R, Blackwell TS, Banovich NE, Kropski JA. Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. *Sci Adv* 2020;6:eaba1972.
14. Morse C, Tabib T, Sembrat J, Buschur KL, Bittar HT, Valenzi E, Jiang Y, Kass DJ, Gibson K, Chen W, Mora A, Benos PV, Rojas M, Lafyatis R. Proliferating SPP1/MERTK-expressing

- macrophages in idiopathic pulmonary fibrosis. *Eur Respir J* 2019;54:1802441.
15. Mayr CH, Simon LM, Leuschner G, Ansari M, Schniering J, Geyer PE, Angelidis I, Strunz M, Singh P, Kneidinger N, Reichenberger F, Silbernagel E, Böhm S, Adler H, Lindner M, Maurer B, Hilgendorff A, Prasse A, Behr J, Mann M, Eickelberg O, Theis FJ, Schiller HB. Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers. *EMBO Mol Med* 2021;13:e12871.
16. Carrington R, Jordan S, Wong YJ, Pitchford SC, Page CP. A novel murine model of pulmonary fibrosis: the role of platelets in chronic changes induced by bleomycin. *J Pharmacol Toxicol Methods* 2021;109:107057.
17. In 't Veld SGJG, Wurdinger T. Tumor-educated platelets. *Blood* 2019;133:2359–2364.
18. Ntoliou P, Papanas N, Nena E, Boglou P, Koulelidis A, Tzouvelekis A, Xanthoudaki M, Tsigalou C, Froudarakis ME, Bouros D, Mikhailidis DP, Steiropoulos P. Mean Platelet Volume as a Surrogate Marker for Platelet Activation in Patients With Idiopathic Pulmonary Fibrosis. *Clin Appl Thromb Hemost* 2016;22:346–350.
19. Crooks MG, Fahim A, Naseem KM, Morice AH, Hart SP. Increased Platelet Reactivity in Idiopathic Pulmonary Fibrosis Is Mediated by a Plasma Factor. *PLoS One* 2014;9:.
20. O'Dwyer DN, Norman KC, Xia M, Huang Y, Gurczynski SJ, Ashley SL, White ES, Flaherty KR, Martinez FJ, Murray S, Noth I, Arnold KB, Moore BB. The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel


- immunological processes. *Sci Rep* 2017;7:46560.
21. Chong DLW, Mikolasch TA, Sahota J, Rebeyrol C, Garthwaite HS, Booth HL, Heightman M, José RJ, Khawaja AA, Labelle M, Scotton CJ, Porter JC. *Platelet counts predict prognosis in IPF, but are not the main source of pulmonary TGF β 1*. 2020. doi:10.1101/2020.03.06.978874.
22. Scott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, Chen S, Carns MA, Aren K, Sun J, Koloms K, Lee J, Baral J, Kropski J, Zhao H, Herzog E, Martinez FJ, Moore BB, Hinchcliff M, Denny J, Kaminski N, Herazo-Maya JD, Shah NH, Khatri P. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. *Lancet Respir Med* 2019;7:497–508.
23. Teoh AKY, Jo HE, Chambers DC, Symons K, Walters EH, Goh NS, Glaspole I, Cooper W, Reynolds P, Moodley Y, Corte TJ. Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry. *Eur Respir J* 2020;55:1901855.
24. Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, Atwood M, Kirchgaessler K-U, Maher TM. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2021;204:74–81.
25. Karampitsakos T, Torrisi S, Antoniou K, Manali E, Korbila I, Papaioannou O, Sampsonas F, Katsaras M, Vasarmidi E, Papakosta D, Domvri K, Fouka E, Organtzis I, Daniil Z, Dimeas I, Kirgou P, Gourgoulialis KI, Papanikolaou IC, Markopoulou K, Kounti G, Tsapakidou E,

- Papadopoulou E, Tatsis K, Gogali A, Kostikas K, Tzilas V, Chrysikos S, Papiris S, Bouros D, *et al.* Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. *Respir Res* 2021;22:140.
26. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* 2015;12:453–457.
27. Vallania F, Tam A, Lofgren S, Schaffert S, Azad TD, Bongen E, Haynes W, Alsup M, Alonso M, Davis M, Engleman E, Khatri P. Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases. *Nat Commun* 2018;9:4735.
28. Suess PM, China LE, Pilling D, Gomer RH. Extracellular Polyphosphate Promotes Macrophage and Fibrocyte Differentiation, Inhibits Leukocyte Proliferation, and Acts as a Chemotactic Agent for Neutrophils. *J Immunol* 2019;203:493–499.


Figures

Figure 1

A



B



C




Figure 2








Figure 3

A



B



C




Figure 4




Figure 5






Figure 6

A



B Survival_Platelet Gene Signature in BAL Fluid




Figure 7




Figure 8






Figure 9

A

Lung Transplant-Free Survival



B

Lung Transplant-Free Survival




Figure 10

